Aquestive Therapeutics faces a securities class action lawsuit covering the period June 16, 2025 to January 8, 2026. The company allegedly made false statements about its Anaphylm drug application while concealing material facts about human factors in the sublingual film's use. On January 9, 2026, the FDA identified deficiencies that delayed approval, causing the stock to plummet 37% in a single day from $6.21 to $3.91 per share.

A class action lawsuit has been filed against Aquestive Therapeutics and certain officers for alleged securities fraud. The complaint alleges that defendants made materially false statements regarding the timeline for FDA approval of Anaphylm and concealed significant human factors risks associated with the sublingual film product that could impact regulatory approval.

A class action lawsuit has been filed against Aquestive Therapeutics for allegedly misleading investors about FDA approval prospects for its Anaphylm drug. The company failed to disclose FDA-identified deficiencies that precluded approval by the January 31, 2026 deadline, resulting in a 37% stock price decline on January 9, 2026. Investors have until May 4, 2026 to apply as lead plaintiff.

Rosen Law Firm is notifying investors in Aquestive Therapeutics, Franklin BSP Realty Trust, and ImmunityBio about ongoing securities class action lawsuits. Investors who purchased securities during specified class periods are encouraged to secure legal counsel before important deadlines. The lawsuits allege false or misleading statements regarding product applications and disclosures.

Rosen Law Firm has filed securities class action lawsuits against Franklin BSP Realty Trust (FBRT) and other companies, alleging that defendants made false and misleading statements about business prospects and dividend sustainability during the Class Period. Investors with losses exceeding $100,000 are encouraged to join the class action before the April 27, 2026 lead plaintiff deadline.

Law firm Holzer & Holzer announces lead plaintiff deadlines for multiple shareholder class action lawsuits against pharmaceutical and energy companies. Aquestive Therapeutics faces allegations regarding false statements about its Anaphylm drug application, Nektar Therapeutics regarding its REZOLVE-AA trial, and Eos Energy Enterprises regarding production capacity guidance. Investors who suffered losses during the specified periods are encouraged to seek lead plaintiff status.

Aquestive Therapeutics faces a securities class action lawsuit alleging management made materially misleading statements about the regulatory approval timeline for its Anaphylm product. The stock dropped over 37% on January 9, 2026, after FDA deficiencies in the NDA became public. Institutional investors are being sought as lead plaintiffs, with a May 4, 2026 deadline for applications.

A class action lawsuit has been filed against Aquestive Therapeutics for alleged securities fraud. The complaint alleges that defendants made materially false and misleading statements regarding the timeline for FDA approval of Anaphylm and concealed significant human factors risks associated with the sublingual film product. Investors who purchased securities between June 16, 2025 and January 8, 2026 may be eligible to join the class action.

Rosen Law Firm has filed securities class action lawsuits against Franklin BSP Realty Trust, Driven Brands Holdings Inc., and Aquestive Therapeutics, Inc. The firm is seeking lead plaintiffs and encouraging investors who purchased securities during specified class periods to join the litigation. The lawsuits allege that defendants made false or misleading statements regarding business prospects and financial performance.

Rosen Law Firm has filed securities class action lawsuits against Aquestive Therapeutics, ODDITY Tech Ltd., and NuScale Power Corporation. The primary case detailed involves Aquestive, where investors who purchased securities between June 16, 2025 and January 8, 2026 may be entitled to compensation. The lawsuit alleges that Aquestive made false statements regarding its New Drug Application for Anaphylm, specifically concealing human factors issues related to packaging, use, administration, and labeling. The lead plaintiff deadline is May 4, 2026.

The Portnoy Law Firm has announced a class action lawsuit against Aquestive Therapeutics on behalf of investors who purchased securities between June 16, 2025 and January 8, 2026. The lawsuit alleges that Aquestive made false statements about FDA approval prospects for its Anaphylm drug and failed to disclose that the FDA identified deficiencies in the NDA application. Following the January 9, 2026 disclosure of these deficiencies, Aquestive's stock price fell more than 37%. The deadline for filing a lead plaintiff motion is May 4, 2026.

Aquestive Therapeutics faces a securities fraud lawsuit after management repeatedly assured investors that its Anaphylm drug was 'on track' for FDA approval by January 31, 2026. However, on January 9, 2026, the FDA identified critical deficiencies, and by January 30, 2026, issued a Complete Response Letter citing human factors validation failures. AQST stock plummeted 37% (from $6.21 to $3.91) on the news. The lawsuit alleges management knew or recklessly disregarded these deficiencies while providing false confidence statements that artificially inflated the stock price.